Exclusive Summary

• Prednisolone 5mg tablets are a mature generic drug, and the Chinese supplier's US FDA GMP certification and existing US registration provide a solid foundation for rapid market expansion.
• The product addresses a wide range of inflammatory diseases, ensuring stable demand and a large global patient base.
• Its inclusion in the WHO Essential Medicines List and recommendation in treatment guidelines as a first-/second-line therapy solidify its clinical value and market acceptance.
• Leveraging its US market launch experience, the generic drug offers a competitive advantage in quality and market access over other generics.
• The US FDA GMP certification and existing US registration demonstrate high quality and compliance, reducing risk for potential global distribution partners.